Suchergebnisse - "rucaparib"

PubPharm (53)

1

The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Brown, T. | Yablonovitch, A. | Till, J. | +11

CommentIn: Clin Cancer Res. 2023 Dec 15;29(24):5005-5007. - PMID 37787975

2

Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations

enthalten in: The Annals of pharmacotherapy | 2023

von Pan, Y. | Hood, A. | Ahmad, H. | +1

3

Rucaparib improves PFS in patients with BRCA1/2-altered mCRPC

enthalten in: Nature reviews. Urology | 2023

von Stone, L.

CommentOn: N Engl J Med. 2023 Feb 23;388(8):719-732. - PMID 36795891

4

The effect of PARP inhibitors in homologous recombination proficient ovarian cancer : meta-analysis

enthalten in: Journal of chemotherapy (Florence, Italy) | 2023

von Skelin, M. | Šarčević, D. | Lešin Gaćina, D. | +3

5

Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations

enthalten in: The Lancet. Oncology | 2022

von Ganguly, S. | Gogia, A.

CommentOn: Lancet Oncol. 2022 Apr;23(4):465-478. - PMID 35298906

6

Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations - Authors' reply

enthalten in: The Lancet. Oncology | 2022

von Kristeleit, R. | Oza, A.

CommentOn: Lancet Oncol. 2022 Apr;23(4):465-478. - PMID 35298906

7

Rucaparib for BRCA1/2-mutated pretreated ovarian cancer : reflections from the ARIEL4 trial

enthalten in: The Lancet. Oncology | 2022

von O'Donnell, D.

CommentOn: Lancet Oncol. 2022 Apr;23(4):465-478. - PMID 35298906

8

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4) : an international, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2022

von Kristeleit, R. | Lisyanskaya, A. | Fedenko, A. | +22

CommentIn: Lancet Oncol. 2022 Apr;23(4):440-441. - PMID 35298905

9

Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2

enthalten in: European journal of medicinal chemistry | 2022

von Yu, J. | Luo, L. | Hu, T. | +6

10

Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer

enthalten in: Gynecologic oncology | 2021

von Swisher, E. | Kristeleit, R. | Oza, A. | +19

1
2
3
4
5
6
Nächster »
[6]